Research programme: monoclonal antibody therapeutics - Bolden Therapeutics
Latest Information Update: 19 Feb 2021
At a glance
- Originator Bolden Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 18 Feb 2021 Preclinical trials in CNS disorders in USA (Parenteral)